Cure My Disease

Don't miss your cure!

 Log in / Sign up

Off-the-Shelf CAR-T cells take on tough blood cancers

NCT ID NCT07284433

Recruiting now Disease control Sponsor: AvenCell Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new CAR-T therapy made from donor cells, so it's ready to use without waiting for a patient's own cells to be modified. It targets two proteins on cancer cells to lower the chance of the cancer coming back. About 178 adults with relapsed or refractory B-cell lymphoma or leukemia will receive one infusion after chemotherapy. The main goals are to find a safe dose and see how many patients achieve complete remission by week 13.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Allo-QuadCAR01-T (donor CAR-T cells targeting CD19 and CD20)
What this could lead to
If it works, this could provide a faster, cheaper off-the-shelf treatment option for patients with relapsed or refractory B-cell cancers.
What could go wrong
This is an early Phase 1/2 trial, so safety and effectiveness are not yet proven. There are risks of severe side effects like cytokine release syndrome or graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia B-cell non-Hodgkin lymphoma diffuse large B-cell lymphoma hematopoietic and lymphoid cell neoplasm leukemia lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA AND LYMPHOMA LEUKEMIA RELAPSE LYMPHOMA RECEIVING CAR-T THERAPY LYMPHOMA, DIFFUSE LARGE B-CELL

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brown University Health

    NOT_YET_RECRUITING

    Providence, Rhode Island, 02903, United States

    Contact Email: •••••@•••••

  • Charité Universitätsmedizin Berlin

    RECRUITING

    Berlin, 13353, Germany

    Contact Email: •••••@•••••

  • Klinikum der Universität München

    NOT_YET_RECRUITING

    Munich, Bavaria, 81377, Germany

    Contact Email: •••••@•••••

  • MD Anderson Cancer Center

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

    Contact Email: •••••@•••••

  • Northwestern University

    NOT_YET_RECRUITING

    Evanston, Illinois, 60208, United States

    Contact Email: •••••@•••••

  • Sarah Cannon Research Institute

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact Email: •••••@•••••

  • Uniklinikum Erlangen

    NOT_YET_RECRUITING

    Essen, North Rhine-Westphalia, 45147, Germany

    Contact Email: •••••@•••••

  • University of Chicago

    NOT_YET_RECRUITING

    Chicago, Illinois, 60637, United States

    Contact Phone: •••-•••-••••

  • Universitätsklinikum Dresden

    RECRUITING

    Dresden, Saxony, 01307, Germany

    Contact Email: •••••@•••••

  • Universitätsklinikum Erlangen

    RECRUITING

    Erlangen, Bavaria, 91054, Germany

    Contact Email: •••••@•••••

  • Universitätsklinikum Hamburg-Eppendorf

    NOT_YET_RECRUITING

    Hamburg, 20246, Germany

    Contact Email: •••••@•••••

  • Universitätsklinikum Marburg

    NOT_YET_RECRUITING

    Marburg, Hesse, 35032, Germany

    Contact Email: •••••@•••••

  • Universitätsklinikum Ulm

    RECRUITING

    Ulm, Baden-Wurttemberg, 89081, Germany

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.